Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings. The company has decided to discontinue hosting quarterly financial results conference calls.
The company's management team will participate in three major healthcare investor conferences in March: the TD Cowen 45th Annual Health Care Conference in Boston on March 3, the Leerink Partners Global Healthcare Conference in Miami on March 10, and the Barclays 27th Annual Global Healthcare Conference in Miami on March 11. All presentations will be in a fireside chat format and will be accessible via webcast on the company's website for approximately 30 days after each event.
Editas Medicine (EDIT) has announced significant progress in its gene editing programs, highlighting new preclinical proof of concept data and strategic priorities through 2027. The company achieved in vivo preclinical proof of concept for editing hematopoietic stem cells (HSCs) in non-human primates and demonstrated successful liver cell editing, marking important steps toward treating sickle cell disease and beta thalassemia.
Key 2025 milestones include declaring two in vivo development candidates and presenting additional preclinical data. The company's 2025-2027 strategic priorities include submitting at least one IND/CTA, achieving human in vivo proof of concept, and initiating late-stage trials.
Financially, Editas reports approximately $270 million in cash and equivalents as of December 31, 2024, with an operational runway extending into Q2 2027.
Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Gilmore O'Neill, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
Interested parties can access a live webcast of the presentation through the "Investors" section of the Editas Medicine website. The presentation recording will remain available on the company's website for approximately 30 days after the event.
Editas Medicine (EDIT) announced a strategic transition to focus exclusively on in vivo CRISPR-edited medicines, following recent breakthroughs in preclinical studies. The company achieved ~40% editing of the HBG1/2 promoter site using their proprietary targeted lipid nanoparticle delivery system, resulting in 20% HbF expressing human red blood cells. They also demonstrated high-efficiency liver editing in non-human primates.
As part of this transition, Editas is ending development of reni-cel and implementing significant cost-saving measures, including a 65% workforce reduction over the next six months. Several management changes were announced, including the departure of Chief Medical Officer Baisong Mei and two board members. The restructuring is expected to extend the company's cash runway into Q2 2027.
Editas Medicine (NASDAQ: EDIT) presented updated clinical data from the Phase 1/2/3 RUBY trial of reni-cel in 28 patients with severe sickle cell disease (SCD). The trial demonstrated positive results with 27 of 28 patients remaining free of vaso-occlusive events post-treatment. Key findings include early normalization of total hemoglobin from 9.8 g/dL at baseline to 13.8 g/dL at Month 6, and sustained fetal hemoglobin levels above 40%.
The treatment was well-tolerated with a safety profile consistent with myeloablative busulfan conditioning. Patients showed successful engraftment with median times of 23 days for neutrophil and 25 days for platelet engraftment. Only two serious adverse events possibly related to reni-cel were reported. The median follow-up was 9.5 months, with 11 patients having more than one year of follow-up.
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced its participation in three major healthcare investor conferences. The company will be featured in fireside chat sessions at Guggenheim's Inaugural Healthcare Innovation Conference on November 12 at 4:00 p.m. ET in Boston, the Stifel 2024 Healthcare Conference on November 19 at 1:50 p.m. ET in New York, and the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 1:20 p.m. ET in Coral Gables. Live webcasts will be available on the company's website, with replays accessible for approximately 30 days after each event.
Editas Medicine (EDIT) reported Q3 2024 financial results, highlighting a net loss of $62.1 million ($0.75 per share). The company achieved preclinical proof of concept for in vivo HBG1/2 editing in HSPCs using proprietary targeted LNP technology for sickle cell disease and beta thalassemia treatment. Cash position stands at $265.1 million, expected to fund operations into Q2 2026. The company secured a $57 million upfront payment from DRI Healthcare Trust through the sale of certain future license fees. Research and development expenses increased to $47.6 million, while revenues decreased to $0.1 million.
Editas Medicine (Nasdaq: EDIT) announced significant progress towards its 2024 goals, including achieving in vivo preclinical proof of concept for hematopoietic stem and progenitor cell (HSPC) editing. The company utilized its proprietary targeted lipid nanoparticle (tLNP) to achieve a 29% editing level in HSPCs after a single dose, resulting in 20% HbF-expressing human red blood cells. This advancement is important for developing an in vivo treatment for sickle cell disease and beta thalassemia.
Editas also initiated a process to partner or out-license reni-cel, focusing resources on in vivo pipeline development. The company completed enrollment for the RUBY trial for severe sickle cell disease and the EdiTHAL trial for transfusion-dependent beta thalassemia. Additionally, Editas secured $57 million in non-dilutive capital through a sale agreement with DRI Healthcare Trust and ended Q3 2024 with approximately $265 million in cash and equivalents.
Editas Medicine (Nasdaq: EDIT) and Genevant Sciences have announced a collaboration and nonexclusive license agreement to develop in vivo gene editing medicines. The partnership will combine Editas' CRISPR Cas12a genome editing systems with Genevant's proprietary lipid nanoparticle (LNP) technology for two undisclosed targets in Editas' upregulation strategy.
Under the agreement, Genevant has granted Editas a nonexclusive worldwide license for certain LNP technology to develop mRNA-CRISPR Cas12a-LNP products. Genevant is eligible to receive up to $238 million in upfront and contingent milestone payments, as well as tiered royalties on future product sales.
This collaboration aims to advance Editas' vision of becoming a leader in in vivo programmable gene editing medicine, leveraging Genevant's expertise in LNP delivery systems, which have emerged as a preferred approach for delivering gene editing constructs.
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a strategic update webinar scheduled for Tuesday, October 22, 2024, at 8:00 a.m. ET. The webinar will focus on the company's progress towards its 2024 goals, including the significant achievement of establishing in vivo preclinical proof of concept.
The presentation will also cover business development and financial updates. Interested parties can access the live and archived webcast through a provided link or via the Events & Presentations page on the company's website. A replay of the webinar will be available in the Investors section of the Editas Medicine website following the conclusion of the event.
This strategic update offers an opportunity for stakeholders to gain insights into Editas Medicine's recent advancements and future directions in the field of gene editing.